It looks like much of the weight that people lose when they take GLP-1 agonists is muscle mass and not necessarily fat mass
The STEP 4 trial, which specifically examined semaglutide withdrawal, showed that participants who stopped the medication regained 6.9% of body weight over 48 weeks, while those who continued treatment lost an additional 7.9%
Review bloodwork, assess side effects, discuss dose optimization, and evaluate progress against expectations
Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
The Danish Medicines Agency has reported 19 cases of NAION among Ozempic users in Denmark, with a noticeable increase in overall cases since the drugs market debut in 2018
It blocks glucagon, a hormone that helps to raise blood sugar levels when required
